Status of vaccine research and development of vaccines for HIV-1

Vaccine

Volumn 34, Issue 26, 2016, Pages 2921-2925

  Safrit, Jeffrey T ^a   Fast, Patricia E ^a   Gieber, Lisa ^a   Kuipers, Hester ^a   Dean, Hansi J ^a,b   Koff, Wayne C ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Takeda Vaccines Inc   (United States)

Author keywords

AIDS; HIV; Prevention; Vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; EPITOPE; NEUTRALIZING ANTIBODY;

ARTICLE; DRUG RESEARCH; FINANCIAL MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); HIV INFECTIONS; IMMUNOLOGY; MEDICAL RESEARCH; TRENDS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; BIOMEDICAL RESEARCH; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; EPITOPES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84964618106     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.074     Document Type: Article

References (33)

1. Gottlieb M.S., Schroff R., Schanker H.M., Weisman J.D., Fan P.T., Wolf R.A., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305(24):1425-1431.
2. Masur H., Michelis M.A., Greene J.B., Onorato I., Stouwe R.A., Holzman R.S., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305(24):1431-1438.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) How AIDS Changed Everything: 2015 Global Statistics Fact Sheet. Genenva, Switzerland 2015, http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet [accessed 26.07.15].
4. Kuritzkes D.R., Koup R.A. Human immunodeficiency viruses. Fields virology 2013, 1561-1583. Lippincott Williams and Wilkins, Philadelphia, PA. 6th ed.
5. U.S. Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. [accessed 26.07.15]. http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm.
6. How AIDS Changed Everything: MDG 6: 15 Years, 15 Lessons of Hope from the AIDS Response. Joint United Nations Programme on HIV/AIDS. [accessed 27.07.15]. http://www.unaids.org/en/resources/documents/2015/MDG6_15years-15lessonsfromtheAIDSresponse.
7. Cohen M.S., McCauley M., Gamble T.R. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012, 7(2):99-105.
8. Harmon T.M., Fisher K.A., McGlynn M.G., Stover J., Warren M.J., Teng Y., et al. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries. PLoS ONE 2016, 11(1):e0146387.
9. Walker B.D., Yu X.G. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 2013, 13(7):487-498.
10. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473(7348):523-527.
11. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83(14):7337-7348.
12. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012, 12(4):396-407.
13. Girard M.P., Koff W.C. Human immunodeficiency virus vaccines. Vaccines 2012, 1097-1121. Sanders, Philadelphia, PA. 6th ed. S.A. Plotkin, W. Orenstein, P.A. Offit (Eds.).
14. Autran B. Toward a cure for HIV-Seeking effective therapeutic vaccine strategies. Eur J Immunol 2015, 45(12):3215-3221.
15. Mylvaganam G.H., Silvestri G., Amara R.R. HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol 2015, 35:1-8.
16. International AIDS Vaccine Inititaive (IAVI) Clinical Trials Database. IAVI. [accessed 27.07.15]. http://www.iavi.org/.
17. Schiffner T., Sattentau Q.J., Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology 2013, 10:72.
18. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013, 369(22):2083-2092.
19. Fouda G.G., Cunningham C.K., Permar S.R. Infant HIV-1 vaccines: supplementing strategies to reduce maternal-child transmission. JAMA 2015, 313(15):1513-1514.
20. Safrit J.T. HIV vaccines in infants and children: past trials, present plans and future perspectives. Curr Mol Med 2003, 3(3):303-312.
21. O'Connell R.J., Excler J.L. HIV vaccine efficacy and immune correlates of risk. Curr HIV Res 2013, 11(6):450-463.
22. Mothe B., Hu X., Llano A., Rosati M., Olvera A., Kulkarni V., et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med 2015, 13:60.
23. Hansen S.G., Sacha J.B., Hughes C.M., Ford J.C., Burwitz B.J., Scholz I., et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 2013, 340(6135):1237874.
24. Excler J.L., Tomaras G.D., Russell N.D. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013, 8(5):421-431.
25. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U., et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014, 22(2):464-475.
26. Barouch D.H., Stephenson K.E., Borducchi E.N., Smith K., Stanley K., McNally A.G., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013, 155(3):531-539.
27. Sattentau Q.J. Immunogen design to focus the B-cell repertoire. Curr Opin HIV AIDS 2014, 9(3):217-223.
28. Jardine J.G., Ota T., Sok D., Pauthner M., Kulp D.W., Kalyuzhniy O., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015, 349(6244):156-161.
29. Caskey M., Klein F., Lorenzi J.C., Seaman M.S., West A.P., Buckley N., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015, 522(7557):487-491.
30. Schnepp B.C., Johnson P.R. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS 2014, 9(3):250-256.
31. Forthal D., Hope T.J., Alter G. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS 2013, 8(5):393-401.
32. HIV Prevention Research & Development Funding Trends, 2000-2014 2015, HIV Resource Tracking Working Group, http://www.hivresourcetracking.org/ [accessed 27.07.15].
33. The potential impact of an AIDS vaccine in low- and middle-income countries. IAVI Policy Brief 2012, http://www.iavi.org/publications/file/70-the-potential-impact-of-an-aids-vaccine-in-low-and-middle-income-countries [accessed 27.07.15].